Visus Therapeutics cashes in €20m from L...Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia more ➔
Protein may help control cancer cellsThe protein eIF4A3 may hold the key for future cancer treatments, Karolinska researchers find. more ➔
British drug developer Mission Therapeutic...British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration. more ➔
Bayer takes over VividionThe big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics. more ➔
Spectricity raises €14m in Series B roun... Belgian semiconductor specialist Spectricity BV has baged €14m to speed up the development of mobile hyperspectral sensors for medical applications. more ➔
Sanofi snaps up mRNA partner for US$3.2bnSanofi further launches into the messenger RNA space with US$3.2bn buy-out of mRNA pioneer Translate Bio. more ➔
Abcam to acquire BioVision for $340mLife sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m. more ➔
Byondis and Glycotope merge platforms to t...Cancer and autoimmunity specialist Byondis BV and carbohydrate-targeting antibody company Glycotope have entered into a platform access agreement. more ➔
Artios Pharma Ltd raises US-$153m Series C...Cancer specialist Artios Pharma has raised $153m in a Series C Financing led by Omega Funds and TCG X to progress its clinical pipeline. more ➔
AXA IM Alts raises €1.9bn European Life...AXA IM Alts has raised €1.9bn of equity to accelerate investments into the Life Sciences sector. more ➔
